The effects of phytoestrogen isoflavones on bone density in women: A double-blind, randomized, placebo-controlled trial1-3

American Journal of Clinical Nutrition

Volumn 79, Issue 2, 2004, Pages 326-333

  Atkinson, Charlotte ^a   Compston, Juliet E ^b   Day, Nicholas E ^a   Dowsett, Mitch ^c   Bingham, Sheila A ^d,e  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Body composition; Bone density; Estrogen and vitamin D receptor polymorphisms; Isoflavones; Phytoestrogens; Randomized controlled trial

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOCHANIN A; BIOCHEMICAL MARKER; DAIDZEIN; FORMONONETIN; GENISTEIN; ISOFLAVONE; PHYTOESTROGEN; PLACEBO; ESTRADIOL; ISOFLAVONE DERIVATIVE; PLANT MEDICINAL PRODUCT;

ADULT; ARTICLE; BODY COMPOSITION; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG DETERMINATION; DRUG EFFECT; FEMALE; HEALTH STATUS; HIP; HUMAN; LUMBAR SPINE; MENOPAUSE; OSSIFICATION; OSTEOLYSIS; PROTECTION; RANDOMIZED CONTROLLED TRIAL; RED CLOVER; TREATMENT OUTCOME; AGED; BLOOD; BODY MASS; BONE; METABOLISM; MIDDLE AGED;

TRIFOLIUM PRATENSE;

AGED; BODY MASS INDEX; BONE AND BONES; BONE DENSITY; DOUBLE-BLIND METHOD; ESTRADIOL; FEMALE; HUMANS; ISOFLAVONES; MIDDLE AGED; PHYTOESTROGENS; PLANT PREPARATIONS;

EID: 1342328575     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/79.2.326     Document Type: Article

References (58)

1. Castelo-Branco C, Figueras F, Sanjuan A, Pons F, Vicente JJ, Vanrell JA. Long-term postmenopausal hormone replacement therapy effects on bone mass: differences between surgical and spontaneous patients. Eur J Obstet Gynecol Reprod Biol 1999;83:207-11.
2. Pilon D, Castilloux AM, LeLorier J. Estrogen replacement therapy: determinants of persistence with treatment. Obstet Gynecol 2001;97:97-100.
3. Castelo-Branco C, Figueras F, Sanjuan A, et al. Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation. Menopause 1999;6:307-11.
4. Reinli K, Block G. Phytoestrogen content of foods - a compendium of literature values. Nutr Cancer 1996;26:123-48.
5. Liggins J, Bluck LJ, Runswick S, Atkinson C, Coward WA, Bingham SA. Daidzein and genistein contents of vegetables. Br J Nutr 2000;84:717-25.
6. Setchell KDR, Adlercreutz H. Mammalian lignans and phyto-oestrogens: recent studies on their formation, metabolism and biological role in health and disease. In: Rowland I, ed. Role of the gut flora in toxicity and cancer. London: Academic Press, 1988:315-45.
7. Setchell KD, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. J Nutr 1999;129:758S-67S.
8. Ling X, Lu A, Zhao X, Chen X, Cummings SR. Very low rates of hip fracture in Beijing, People's Republic of China: the Beijing Osteoporosis Project. Am J Epidemiol 1996;144:901-7.
9. Lau EM, Cooper C. The epidemiology of osteoporosis. The oriental perspective in a world context. Clin Orthop 1996;323:65-74.
10. Arjmandi BH, Alekel L, Hollis BW, et al. Dietary soybean protein prevents bone loss in an ovariectomized rat model of osteoporosis. J Nutr 1996;126:161-7.
11. Harrison E, Adjei A, Ameho C, Yamamoto S, Kono S. The effect of soybean protein on bone loss in a rat model of postmenopausal osteoporosis. J Nutr Sci Vitaminol (Tokyo) 1998;44:257-68.
12. Arjmandi BH, Getlinger MJ, Goyal NV, et al. Role of soy protein with normal or reduced isoflavone content in reversing bone loss induced by ovarian hormone deficiency in rats. Am J Clin Nutr 1998;68(suppl):1358S-63S.
13. Greendale GA, FitzGerald G, Huang MH, et al. Dietary soy isoflavones and bone mineral density: results from the study of women's health across the nation. Am J Epidemiol 2002;155:746-54.
14. Mei J, Yeung SS, Kung AW. High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J Clin Endocrinol Metab 2001;86:5217-21.
15. Horiuchi T, Onouchi T, Takahashi M, Ito H, Orimo H. Effect of soy protein on bone metabolism in postmenopausal Japanese women. Osteoporos Int 2000;11:721-4.
16. Ho SC, Chan SG, Yi Q, Wong E, Leung PC. Soy intake and the maintenance of peak bone mass in Hong Kong Chinese women. J Bone Miner Res 2001;16:1363-9.
17. Somekawa Y, Chiguchi M, Ishibashi T, Aso T. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet Gynecol 2001;97:109-15.
18. Nagata C, Shimizu H, Takami R, Hayashi M, Takeda N, Yasuda K. Soy product intake and serum isoflavonoid and estradiol concentrations in relation to bone mineral density in postmenopausal Japanese women. Osteoporos Int 2002;13:200-4.
19. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998;68(suppl):1375S-9S.
20. Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause 2001;8:259-65.
21. Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 2000;72: 844-52.
22. Scheiber MD, Liu JH, Subbiah MT, Rebar RW, Setchell KD. Dietary inclusion of whole soy foods results in significant reductions in clinical risk factors for osteoporosis and cardiovascular disease in normal postmenopausal women. Menopause 2001;8:384-92.
23. Chicchi LM, Secreto G, D'Amore M, et al. Efficacy of a soy rich diet in preventing postmenopausal osteoporosis: the Menfis randomized trial. Maturitas 2002;42:295-300.
24. Uesugi T, Fukui Y, Yamori Y. Beneficial effects of soybean isoflavone supplementation on bone metabolism and serum lipids in postmenopausal Japanese women: a four-week study. J Am Coll Nutr 2002;21:97-102.
25. Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebocontrolled study. Menopause 2000;7:236-42.
26. Knight DC, Howes JB, Eden JA, Howes LG. Effects on menopausal symptoms and acceptability of isoflavone-containing soy powder dietary supplementation. Climacteric 2001;4:13-8.
27. Hale GE, Hughes CL, Robboy SJ, Agarwal SK, Bievre M. A double-blind randomized study on the effects of red clover isoflavones on the endometrium. Menopause 2001;8:338-46.
28. Wolfe JN. Breast patterns as an index of risk for developing breast cancer. AJR Am J Roentgenol 1976;126:1130-7.
29. Setchell KD, Brown NM, Desai P, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001;131:1362S-75S.
30. Bingham S, Cummings JH. The use of 4-aminobenzoic acid as a marker to validate the completeness of 24 h urine collections in man. Clin Sci 1983;64:629-35.
31. Johansson G, Bingham S, Vahter M. A method to compensate for incomplete 24-hour urine collections in nutritional epidemiology studies. Public Health Nutr 1999;2:587-91.
32. Setchell KD, Welsh MB, Lim CK. High-performance liquid chromatographic analysis of phytoestrogens in soy protein preparations with ultraviolet, electrochemical and thermospray mass spectrometric detection. J Chromatogr 1987;386:315-23.
33. Franke AA, Custer LJ, Cerna CM, Narala K. Rapid HPLC analysis of dietary phytoestrogens from legumes and from human urine. Proc Soc Exp Biol Med 1995;208:18-26.
34. Pratt DA, Daniloff Y, Duncan A, Robins SP. Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography. Anal Biochem 1992;207:168-75.
35. Gomez B Jr, Ardakani S, Ju J, et al. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 1995;41:1560-6.
36. Melkko J, Kauppila S, Niemi S, et al. Immunoassay for intact amino-terminal propeptide of human type I procollaaen. Clin Chem 1996;42:947-54.
37. Dowsett M, Goss PE, Powles TJ, et al. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res 1987;47:1957-61.
38. Bingham SA, Welch AA, McTaggart A, et al. Nutritional methods in the European Prospective Investigation of Cancer in Norfolk. Public Health Nutr 2001;4:847-58.
39. Cooper C. Bone mass throughout life: bone growth and involution. In: Francis RM, Dick WC, eds. Osteoporosis: pathogenesis and management. Dordrecht, Netherlands: Kluwer Academic Publishers, 1990:1-26.
40. Reeve J. Clinical assessment of the physical properties of bone. In: Compston JE, ed. Osteoporosis: new perspectives on causes, prevention and treatment. London: Royal College of Physicians of London, 1996:41-53.
41. Anderson JJ, Chen X, Boass A, et al. Soy isoflavones: no effects on bone mineral content and bone mineral density in healthy, menstruating young adult women after one year. J Am Coll Nutr 2002;21:388-93.
42. Nestel PJ, Yamashita T, Sasahara T, et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol 1997;17:3392-8.
43. Hodgson JM, Puddey IB, Beilin LJ, Mori TA, Croft KD. Supplementation with isoflavonoid phytoestrogens does not alter serum lipid concentrations: a randomized controlled trial in humans. J Nutr 1998;128:728-32.
44. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995;333:276-82.
45. Barnes S. Phytoestrogens and breast cancer. Baillieres Clin Endocrinol Metab 1998;12:559-79.
46. Clarkson TB, Anthony MS. Phytoestrogens and coronary heart disease. Baillieres Clin Endocrinol Metab 1998;12:589-604.
47. Eden J. Phytoestrogens and the menopause. Baillieres Clin Endocrinol Metab 1998;12:581-7.
48. Fanti O, Faugere MC, Gang Z, Schmidt J, Cohen D, Malluche HH. Systematic administration of genistein partially prevents bone loss in ovariectomized rats in a nonestrogen-like mechanism. Am J Clin Nutr 1998;68(suppl):1517S(abstr).
49. Looker AC, Bauer DC, Chesnut CH III, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 2000;11:467-80.
50. Cleary MP, Maihle NJ. The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med 1997;216:28-43.
51. Bjorntorp P. Abdominal fat distribution and disease: an overview of epidemiological data. Ann Med 1992;24:15-8.
52. Pi-Sunyer FX. Health implications of obesity. Am J Clin Nutr 1991;53(suppl):1595S-603S.
53. Poehlman ET, Toth MJ, Gardner AW. Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann Intern Med 1995;123:673-5.
54. Svendsen OL, Hassager C, Christiansen C. Age- and menopause-associated variations in body composition and fat distribution in healthy women as measured by dual-energy X-ray absorptiometry. Metabolism 1995;44:369-73.
55. Tremollieres FA, Pouilles JM, Ribot CA. Relative influence of age and menopause on total and regional body composition changes in postmenopausal women. Am J Obstet Gynecol 1996;175:1594-600.
56. Perrone G, Liu Y, Capri O, et al. Evaluation of the body composition and fat distribution in long-term users of hormone replacement therapy. Gynecol Obstet Invest 1999;48:52-5.
57. Reubinoff BE, Wurtman J, Rojansky N, et al. Effects of hormone replacement therapy on weight, body composition, fat distribution, and food intake in early postmenopausal women: a prospective study. Fertil Steril 1995;64:963-8.
58. Sites CK. Hormone replacement therapy: cardiovascular benefits for aging women. Coron Artery Dis 1998;9:789-93.